Cargando…
An O-Antigen Glycoconjugate Vaccine Produced Using Protein Glycan Coupling Technology Is Protective in an Inhalational Rat Model of Tularemia
There is a requirement for an efficacious vaccine to protect people against infection from Francisella tularensis, the etiological agent of tularemia. The lipopolysaccharide (LPS) of F. tularensis is suboptimally protective against a parenteral lethal challenge in mice. To develop a more efficacious...
Autores principales: | Marshall, Laura E., Nelson, Michelle, Davies, Carwyn H., Whelan, Adam O., Jenner, Dominic C., Moule, Madeleine G., Denman, Carmen, Cuccui, Jon, Atkins, Timothy P., Wren, Brendan W., Prior, Joann L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6304830/ https://www.ncbi.nlm.nih.gov/pubmed/30622981 http://dx.doi.org/10.1155/2018/8087916 |
Ejemplares similares
-
Exploitation of bacterial N-linked glycosylation to develop a novel recombinant glycoconjugate vaccine against Francisella tularensis
por: Cuccui, Jon, et al.
Publicado: (2013) -
Recent advances in the production of recombinant glycoconjugate vaccines
por: Kay, Emily, et al.
Publicado: (2019) -
Cytoplasmic glycoengineering of Apx toxin fragments in the development of Actinobacillus pleuropneumoniae glycoconjugate vaccines
por: Passmore, Ian J., et al.
Publicado: (2019) -
Engineering a suite of E. coli strains for enhanced expression of bacterial polysaccharides and glycoconjugate vaccines
por: Kay, Emily J., et al.
Publicado: (2022) -
DNA display of glycoconjugates to emulate oligomeric interactions of glycans
por: Novoa, Alexandre, et al.
Publicado: (2015)